Cagrilintide and CagriSema Documentation Notes for Pharmacy Procurement
How procurement teams should qualify Cagrilintide and CagriSema lots: amylin-analog identity, blend-ratio evidence, COA scope, HPLC/MS, stability, and route-specific testing.
Published May 28, 2026 · 6 min read · By Vialdyne Regulatory Team
Cagrilintide sourcing belongs next to the GLP-1 conversation, but it should not be treated as a generic GLP-1 substitute. Cagrilintide is an amylin-analog research peptide, and CagriSema-style procurement adds a second layer: the buyer must understand whether the offer is separate components, a paired kit, or a defined combination workflow. Each version changes the documentation question.
What documents should buyers request for Cagrilintide or CagriSema?
For Cagrilintide, request a batch-specific COA, HPLC purity trace, MS identity report, water content, counter-ion status, storage guidance, and stability support. For CagriSema-style supply, also request component-level identity evidence for Cagrilintide and Semaglutide, ratio or fill documentation where relevant, and a clear statement of whether the supplier is shipping separate components or a combined preparation.
Cagrilintide-specific review questions
- Is the lot released as Cagrilintide with molecule-specific HPLC and MS evidence?
- Does the COA show the exact lot number, retest date, storage condition, and signed release decision?
- Are counter-ion, water, and residual-solvent results reported rather than implied?
- Can LAL endotoxin and microbial-limit tests be added if the buyer's route or jurisdiction requires them?
- Is stability data available for the actual salt form, vial fill, and storage condition?
CagriSema-style procurement questions
The term CagriSema is often used loosely in sourcing conversations. Procurement should force precision before quote stage:
| Question | Why it matters |
|---|---|
| Separate components or combined supply? | Component-level COAs are easier to verify than vague blend claims. |
| What is the target component ratio? | Ratio evidence affects fill planning and downstream QA. |
| Are both components identity-confirmed? | Semaglutide and Cagrilintide need separate identity evidence. |
| Is stability based on separate vials or combined material? | Stability assumptions do not automatically transfer. |
| Which route or pathway is intended? | Microbiology and endotoxin scope depends on downstream use. |
Procurement posture
For first qualification, do not accept a single summary document that says "CagriSema blend" without component detail. At minimum, request the Cagrilintide COA, Semaglutide COA, HPLC/MS evidence for both components, a fill or ratio statement, storage guidance, and stability availability. If the supplier cannot explain the format, the buyer does not yet know what is being purchased.
How Vialdyne handles requests
Vialdyne asks buyers to specify whether they need Cagrilintide alone, Semaglutide alone, paired component supply, or a defined documentation package for a CagriSema-style workflow. QA then maps the release packet, route-specific add-on testing, stability availability, and lead time before commercial quote.
Talk to our regulatory team
Need Cagrilintide or CagriSema documentation before quote?
Send the format, destination market, and required tests. QA will confirm what can be documented before pricing.